Temsirolimus  	Temsirolimus  	 NNP	B-NP
in  	in  	 IN	O
mantle  	mantle  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lymphoma  	lymphoma  	 NNS	I-NP
and  	and  	 CC	O
other  	other  	 JJ	O
non-Hodgkin  	non-Hodgkin  	 JJ	B-NP
lymphoma  	lymphoma  	 NN	I-NP
subtypes  	subtypes  	 VBD	O
Temsirolimus 	Temsirolimus 	 NNP	B-NP
,  	,  	 ,	O
an  	an  	 DT	O
inhibitor  	inhibitor  	 NN	O
of  	of  	 IN	O
mammalian  	mammalian  	 JJ	B-NP
target  	target  	 NN	I-NP
of  	of  	 IN	I-NP
rapamycin  	rapamycin  	 NNS	I-NP
( 	( 	 -LRB-	O
mTOR 	mTOR 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
has  	has  	 VBZ	O
anti-tumor  	anti-tumor  	 JJ	B-NP
activity  	activity  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
relapsed  	relapsed  	 NN	O
or  	or  	 CC	O
refractory  	refractory  	 JJ	B-NP
mantle  	mantle  	 JJ	I-NP
cell  	cell  	 NN	I-NP
lymphoma  	lymphoma  	 NNS	I-NP
( 	( 	 -LRB-	O
MCL 	MCL 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
other  	other  	 JJ	O
mature  	mature  	 JJ	O
lymphoid  	lymphoid  	 JJ	B-NP
neoplasms.  	neoplasms.  	 NNP	I-NP
mTOR  	mTOR  	 NNP	O
is  	is  	 VBZ	O
an  	an  	 DT	O
intracellular  	intracellular  	 JJ	B-NP
kinase  	kinase  	 NN	I-NP
that  	that  	 WDT	O
controls  	controls  	 VBZ	O
the  	the  	 DT	O
mRNA  	mRNA  	 JJ	B-NP
translation  	translation  	 NN	I-NP
of  	of  	 IN	O
many  	many  	 JJ	O
proteins  	proteins  	 NNS	O
( 	( 	 -LRB-	O
eg 	eg 	 UH	B-NP
,  	,  	 ,	O
cyclin  	cyclin  	 CD	B-NP
D1 	D1 	 CD	I-NP
)  	)  	 -RRB-	O
that  	that  	 WDT	O
can  	can  	 MD	O
act  	act  	 VB	O
as  	as  	 IN	O
oncogenes  	oncogenes  	 NNS	B-NP
and  	and  	 CC	O
contribute  	contribute  	 VB	O
to  	to  	 TO	O
lymphomagenesis 	lymphomagenesis 	 VB	O
.  	.  	 .	O
Characterized  	Characterized  	 VBN	O
by  	by  	 IN	O
overexpression  	overexpression  	 NN	B-NP
of  	of  	 IN	I-NP
cyclin  	cyclin  	 CD	I-NP
D1 	D1 	 CD	I-NP
,  	,  	 ,	O
MCL  	MCL  	 NNP	O
was  	was  	 VBD	O
identified  	identified  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
disease  	disease  	 NN	O
that  	that  	 WDT	O
might  	might  	 MD	O
be  	be  	 VB	O
susceptible  	susceptible  	 JJ	O
to  	to  	 TO	O
mTOR  	mTOR  	 JJ	B-NP
inhibition 	inhibition 	 NN	I-NP
.  	.  	 .	O
When  	When  	 WRB	O
single-agent  	single-agent  	 JJ	B-NP
temsirolimus  	temsirolimus  	 NN	I-NP
was  	was  	 VBD	O
explored  	explored  	 VBN	O
in  	in  	 IN	O
two  	two  	 CD	O
phase  	phase  	 NN	O
II  	II  	 NNP	O
studies  	studies  	 NNS	O
for  	for  	 IN	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
relapsed  	relapsed  	 NN	O
or  	or  	 CC	O
refractory  	refractory  	 JJ	O
MCL 	MCL 	 NNP	O
,  	,  	 ,	O
it  	it  	 PRP	O
demonstrated  	demonstrated  	 VBD	B-NP
anti-tumor  	anti-tumor  	 JJ	I-NP
activity 	activity 	 NN	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
overall  	overall  	 JJ	O
response  	response  	 NN	B-NP
rates  	rates  	 NNS	I-NP
of  	of  	 IN	O
38 	38 	 CD	O
%  	%  	 NN	O
and  	and  	 CC	O
41 	41 	 CD	O
% 	% 	 NN	O
.  	.  	 .	O
Subsequently 	Subsequently 	 RB	O
,  	,  	 ,	O
a  	a  	 DT	O
three-arm 	three-arm 	 JJ	B-NP
,  	,  	 ,	O
randomized  	randomized  	 JJ	B-NP
phase  	phase  	 NN	I-NP
III  	III  	 NNP	I-NP
trial  	trial  	 NN	O
was  	was  	 VBD	O
conducted  	conducted  	 VBN	O
to  	to  	 TO	O
compare  	compare  	 VB	O
two  	two  	 CD	O
dosing  	dosing  	 JJ	O
regimens  	regimens  	 NN	O
of  	of  	 IN	O
temsirolimus  	temsirolimus  	 NN	B-NP
with  	with  	 IN	O
investigator 	investigator 	 NN	O
's  	's  	 POS	O
choice  	choice  	 NN	O
of  	of  	 IN	O
therapy  	therapy  	 NN	O
for  	for  	 IN	O
heavily  	heavily  	 RB	O
pretreated  	pretreated  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
with  	with  	 IN	O
relapsed  	relapsed  	 NN	O
or  	or  	 CC	O
refractory  	refractory  	 JJ	O
MCL  	MCL  	 NNP	O
( 	( 	 -LRB-	O
N  	N  	 NNP	O
=  	=  	 SYM	O
162 	162 	 CD	O
;  	;  	 :	O
randomized  	randomized  	 CD	O
1 	1 	 CD	O
: 	: 	 :	O
1 	1 	 LS	O
: 	: 	 :	O
1 	1 	 LS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Once-weekly  	Once-weekly  	 JJ	B-NP
intravenous  	intravenous  	 NN	O
temsirolimus  	temsirolimus  	 VBD	O
175  	175  	 CD	O
mg  	mg  	 NN	B-NP
for  	for  	 IN	O
3  	3  	 CD	O
weeks  	weeks  	 NNS	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
75  	75  	 CD	O
mg  	mg  	 NNS	B-NP
once  	once  	 RB	O
weekly  	weekly  	 JJ	O
( 	( 	 -LRB-	O
175 	175 	 CD	O
/ 	/ 	 CD	O
75 	75 	 CD	O
)  	)  	 -RRB-	O
significantly  	significantly  	 RB	O
improved  	improved  	 VBN	B-NP
progression-free  	progression-free  	 JJ	I-NP
survival  	survival  	 NN	I-NP
( 	( 	 -LRB-	O
hazard  	hazard  	 NN	B-NP
ratio  	ratio  	 NN	I-NP
=  	=  	 SYM	O
0.44 	0.44 	 CD	O
;  	;  	 :	O
P  	P  	 NN	O
=  	=  	 SYM	O
.0009 	.0009 	 CD	O
)  	)  	 -RRB-	O
versus  	versus  	 CC	O
investigator 	investigator 	 NN	O
's  	's  	 POS	O
choice  	choice  	 NN	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
Median  	Median  	 JJ	B-NP
progression-free  	progression-free  	 JJ	I-NP
survival  	survival  	 NN	I-NP
durations  	durations  	 NNS	I-NP
were  	were  	 VBD	O
4.8  	4.8  	 CD	O
and  	and  	 CC	O
1.9  	1.9  	 CD	O
months 	months 	 NNS	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
The  	The  	 DT	O
objective  	objective  	 JJ	B-NP
response  	response  	 NN	I-NP
rates  	rates  	 NNS	I-NP
were  	were  	 VBD	O
22 	22 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
175 	175 	 CD	O
/ 	/ 	 CD	O
75  	75  	 CD	O
group  	group  	 NN	O
and  	and  	 CC	O
2 	2 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
investigator 	investigator 	 NN	O
's  	's  	 POS	O
choice  	choice  	 NN	B-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
P  	P  	 NN	O
=  	=  	 SYM	O
.0019 	.0019 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
For  	For  	 IN	O
patients  	patients  	 NNS	O
receiving  	receiving  	 VBG	B-NP
temsirolimus 	temsirolimus 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
most  	most  	 RBS	O
frequent  	frequent  	 JJ	O
grade  	grade  	 NN	O
3  	3  	 CD	O
or  	or  	 CC	O
4  	4  	 CD	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
were  	were  	 VBD	O
thrombocytopenia 	thrombocytopenia 	 CD	B-NP
,  	,  	 ,	O
anemia 	anemia 	 NN	B-NP
,  	,  	 ,	O
neutropenia 	neutropenia 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
asthenia 	asthenia 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
results  	results  	 NNS	O
of  	of  	 IN	O
this  	this  	 DT	O
trial  	trial  	 NN	O
established  	established  	 VBD	O
a  	a  	 DT	O
recommended  	recommended  	 JJ	O
clinical  	clinical  	 JJ	B-NP
dose  	dose  	 NN	I-NP
for  	for  	 IN	I-NP
temsirolimus  	temsirolimus  	 JJ	I-NP
monotherapy  	monotherapy  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
relapsed  	relapsed  	 NN	O
or  	or  	 CC	O
refractory  	refractory  	 JJ	O
MCL  	MCL  	 NNP	O
and  	and  	 CC	O
validated  	validated  	 VBG	O
the  	the  	 DT	O
importance  	importance  	 NN	O
of  	of  	 IN	O
mTOR  	mTOR  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
pathogenesis  	pathogenesis  	 NN	B-NP
of  	of  	 IN	O
advanced  	advanced  	 JJ	O
MCL 	MCL 	 NNP	O
.  	.  	 .	O
Objective  	Objective  	 JJ	B-NP
responses  	responses  	 NNS	I-NP
also  	also  	 RB	O
have  	have  	 VBP	O
been  	been  	 VBN	O
reported  	reported  	 VBN	O
for  	for  	 IN	O
other  	other  	 JJ	O
mature  	mature  	 JJ	O
B-cell  	B-cell  	 JJ	B-NP
neoplasms  	neoplasms  	 NNS	I-NP
( 	( 	 -LRB-	O
eg 	eg 	 UH	B-NP
,  	,  	 ,	O
diffuse  	diffuse  	 JJ	O
large  	large  	 JJ	O
B-cell  	B-cell  	 JJ	B-NP
lymphoma  	lymphoma  	 NN	I-NP
or  	or  	 CC	O
follicular  	follicular  	 JJ	B-NP
lymphoma 	lymphoma 	 NN	I-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
phase  	phase  	 NN	O
II  	II  	 NNP	O
setting 	setting 	 NN	O
.  	.  	 .	O
Temsirolimus  	Temsirolimus  	 NNP	B-NP
as  	as  	 IN	O
monotherapy  	monotherapy  	 NN	B-NP
or  	or  	 CC	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
other  	other  	 JJ	O
active  	active  	 JJ	O
agents  	agents  	 NNS	B-NP
warrants  	warrants  	 NNS	I-NP
further  	further  	 JJ	O
investigation  	investigation  	 NN	B-NP
for  	for  	 IN	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
MCL  	MCL  	 NNP	O
and  	and  	 CC	O
other  	other  	 JJ	O
non-Hodgkin  	non-Hodgkin  	 JJ	B-NP
lymphomas 	lymphomas 	 NN	I-NP
.  	.  	 .	O
